Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings estimates for Illumina in a report released on Tuesday, ...

Notable insider trades include Schobel Alexander Mark, Chief Innovation/Tech Officer at Aquestive Therapeutics Inc (AQST), who sold 50000 shares on Mar 15 ’24, at $6 each, totaling $0.30 million. On ...

Shares of Castle Biosciences (NASDAQ: CSTL) tumbled 9% after Novitas, a regional Medicare contractor, finalized its decision not to cover one of the company's cancer tests. The Novitas Medicare ...

Leerink Partners analyst Faisal Khurshid has maintained their neutral stance on GLPG stock, giving a Hold rating on December 23.Stay Ahead of ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...